ExitHealthcare
Catalio Capital Management sells Recognify Life Sciences
RL-007, studied in 500 subjects, adds a second clinical-stage cognition program alongside AmyriAD’s lead asset ismidenon.
- Target
- Recognify Life Sciences
- Source
- PR Newswire
Catalio Capital Management
1 deals covered
1 exit
1 as seller
Most recent deal Wednesday, October 7, 2026.